# Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma

## TL;DR

This study finds that combining cabozantinib and atezolizumab is not cost-effective for treating advanced liver cancer compared to sorafenib in China and the US.

## Contribution

The study evaluates the cost-effectiveness of a new treatment combination for hepatocellular carcinoma in two healthcare systems.

## Key findings

- Cabozantinib plus atezolizumab was not cost-effective compared to sorafenib in China and the US.
- Sorafenib provided greater benefits at a lower cost in both healthcare systems.
- The treatment's cost-effectiveness was most sensitive to survival-related utility values.

## Abstract

Cabozantinib combined with atezolizumab has been shown to prolong progression-free survival in first-line treatment of advanced hepatocellular carcinoma (HCC). However, the cost-effectiveness of this regimen remains unknown. This study aimed to evaluate the cost-effectiveness of cabozantinib plus atezolizumab compared with sorafenib for first-line treatment of advanced HCC from the perspectives of the Chinese health system and the US payers.

A partitioned survival model was constructed based on a phase III randomized clinical trial (COSMIC-312) to compare the health benefits and economic outcomes of cabozantinib plus atezolizumab versus sorafenib for the treatment of hepatocellular carcinoma. Costs and utilities were obtained from published literature. Data recorded included quality-adjusted life years (QALYs), life years (LYs), and incremental cost-effectiveness ratio (ICER). One-way and probabilistic sensitivity analyses were conducted to test the robustness of the results. Subgroup analyses were also performed.

From the perspectives of the US payers and the Chinese health system, the base-case ICER values for cabozantinib plus atezolizumab compared to sorafenib were $-2,731,994.74/QALY and $-2,225,520.14/QALY, respectively. Sorafenib achieved an absolute dominance in terms of cost-effectiveness, offering greater benefits at a lower cost. The models were most sensitive to the utility values for progression-free survival and overall survival. Subgroup analyses also demonstrated that cabozantinib plus atezolizumab was unlikely to be cost-effective as a first-line treatment for advanced HCC.

Cabozantinib plus atezolizumab was not a cost-effective treatment option for HCC when compared to sorafenib from both the Chinese healthcare system and the US payer perspectives.